(Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) is a Blood Derivative owned by CSL, and is involved in 16 clinical trials, of which 12 were completed, 2 are ongoing, and 2 are planned.

Coagulation factors II, VII, IX and X are synthesized in the liver and are collectively called as the prothrombin complex. Factor VII is the zymogen of the active serine protease factor VIIa by which the extrinsic pathway of blood coagulation is initiated. The tissue thromboplastin factor-factor VIIa complex activates coagulation factors IX and X, whereby factor IXa and Xa are formed. With further activation of the coagulation cascade, prothrombin (factor II) is activated and transformed to thrombin. By the action of thrombin, fibrinogen is converted to fibrin, which results in clot formation. The administration of human prothrombin complex provides an increase in plasma levels of the vitamin K-dependent coagulation factors, and can temporarily correct the coagulation defect of patients with deficiency of one or several of these factors.
Protein C human is a zymogen, the activated form of which plays an important role in regulating anticoagulation, inflammation, cell death, and maintaining the permeability of blood vessel walls in humans and other animals.
Protein S human is a vitamin K-dependent plasma glycoprotein synthesized in the endothelium. Protein S in its anti coagulation pathway, functions as a cofactor to Protein C in the inactivation of Factors Va and VIIIa. Only the free form has cofactor activity.

The revenue for (Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) is expected to reach a total of $22.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) NPV Report.

(Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) is currently owned by CSL.

(Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) Overview

Blood coagulation factors II, VII, IX, X, protein C, protein S (Beriplex P/N, Beriplex AU) is a fixed dose combination product, acts as an antihemorrhagic agent. It is formulated as injection lyophilized powder for solution for intravenous route of administration. It is indicated for treatment and perioperative prophylaxis of bleeding in acquired of clotting factor prothrombin complex, such as deficiency caused by treatment with Vitamin K Antagonist, or if antagonist overdose of vitamin K deficiency, when necessary rapid correction of the deficiency thereof, treatment and perioperative prophylaxis in cases of bleeding in congenital deficiency of any of the factors dependent coagulation vitamin K, when not available purified products of the specific factor. It is under development for the treatment of trauma  It was also under development for the treatment of unspecified indications.

It is under development for the treatment of massive haemorrhage associated with severe traumatic injury.

CSL Overview

CSL discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.

The company reported revenues of (US Dollars) US$10,561.9 million for the fiscal year ended June 2022 (FY2022), an increase of 2.4% over FY2021. The operating profit of the company was US$2,927.4 million in FY2022, compared to an operating profit of US$3,130 million in FY2021. The net profit of the company was US$2,254.7 million in FY2022, compared to a net profit of US$2,375 million in FY2021.

Quick View – (Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human))

Report Segments
  • Innovator (NME)
Drug Name
  • (Coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human))
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
  • Other Diseases
  • Undisclosed
Key Companies
  • Sponsor Company: CSL
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.